Adynxx AAQS

What does Adynxx do? Adynxx Inc. is a biotechnology company focused on the development of novel, non-opioid-based pain therapies. The company was founded in 2007 in San Francisco, California, and has since pursued ambitious goals in the field of pain treatment. Adynxx has raised over $65 million in investments since its inception and has an experienced team of experts from the pharmaceutical industry, academic researchers, and business professionals. The company's business model is based on offering non-opioid pain therapy based on the blocking of the Kv1.7 protein. Adynxx aims to use this therapy in various areas such as surgery, acute pain management, and chronic pain treatment. The company employs an agile approach to clinical studies, allowing for quick adaptation to new insights and optimization of the effectiveness and safety of pain treatment. Adynxx operates in three areas: surgery, acute pain management, and chronic pain. Each division aims to provide pain patients with an effective alternative to opioid-based pain medications. The product line includes various non-opioid analgesics based on the blocking of the Kv1.7 protein. The flagship product, AYX1, is currently in Phase II clinical trials. It is an injection administered before or during surgery to relieve pain and offers up to 72 hours of pain relief. Another product in development is AYX2, intended for the treatment of chronic pain. Adynxx has the potential to fundamentally change pain treatment and provide a safe alternative to opioid-based pain medications, offering pain patients effective, safe, and sustainable relief and contributing to an improvement in quality of life. Adynxx is one of the most popular companies on Eulerpool.